[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"organisation-articles-92dcdc14-63b6-4fba-b17f-5f9420063f60":3,"$f33dlrv0sv484s":121,"organisation-92dcdc14-63b6-4fba-b17f-5f9420063f60":123},[4],{"id":5,"title":6,"pubDate":7,"logoUrl":8,"thirdParty":9,"orgId":10,"branches":11,"description":120},"cd503c8e-5053-45e9-a6b5-f25e3798d4e9","Alnylam kondigt landelijk akkoord Nederlandse zorgverzekeraars aan","2019-04-08T14:09:42.187+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Ffile\u002Flogos\u002F92dcdc14-63b6-4fba-b17f-5f9420063f60\u002F3c7524fa-bb74-4a0b-b746-bfa463040164.jpg",false,"92dcdc14-63b6-4fba-b17f-5f9420063f60",[12,16,19,22,25,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72,76,79,83,87,91,95,99,102,105,108,111,114,117],{"id":13,"title":14,"parentId":15},"29141","Gezondheid","29100",{"id":17,"title":18,"parentId":15},"29143","Gezondheidszorg",{"id":20,"title":21,"parentId":15},"94822","Oogverzorging",{"id":23,"title":24,"parentId":15},"94802","Optica",{"id":26,"title":18,"parentId":15},"29118",{"id":28,"title":29,"parentId":15},"29109","Bio-informatica",{"id":31,"title":32,"parentId":15},"29126","Geneesmiddelen",{"id":34,"title":35,"parentId":15},"29179","Geneesmiddelen op voorschrift",{"id":37,"title":38,"parentId":15},"29160","Geneeskunde en uitrusting in het buitenland",{"id":40,"title":41,"parentId":15},"29159","Geneeskunde",{"id":43,"title":44,"parentId":15},"29147","Ziekenhuizen",{"id":46,"title":47,"parentId":15},"29196","Vaccins",{"id":49,"title":50,"parentId":15},"29111","Cardiologie",{"id":52,"title":53,"parentId":15},"29200","Gezondheidsbeheer",{"id":55,"title":56,"parentId":15},"93782","Gezondheidsbeleid",{"id":58,"title":59,"parentId":15},"29149","Immunologie",{"id":61,"title":62,"parentId":15},"29116","Klinische geneeskunde",{"id":64,"title":65,"parentId":15},"29117","Klinische testen",{"id":67,"title":68,"parentId":15},"93772","Medicijnenbeleid",{"id":70,"title":71,"parentId":15},"29158","Medische technologie",{"id":73,"title":74,"parentId":75},"26123","Verzekeringen","26100",{"id":77,"title":78},"12109","Arbeidsmarkt en ondernemen",{"id":80,"title":81,"parentId":82},"12127","Internationaal bedrijfsnieuws","12100",{"id":84,"title":85,"parentId":86},"38105","Nieuws - andere","38100",{"id":88,"title":89,"parentId":90},"93732","Fiscale politiek","41100",{"id":92,"title":93,"parentId":94},"41109","Binnenlandse zaken","28100",{"id":96,"title":97,"parentId":98},"47104","Biotechniek","47100",{"id":100,"title":101,"parentId":98},"47107","Biotechnologie",{"id":103,"title":104,"parentId":98},"47119","Laboratoriumgeneeskunde en -uitrusting",{"id":106,"title":107,"parentId":98},"47123","Microbiologie",{"id":109,"title":110,"parentId":98},"47139","Wetenschap",{"id":112,"title":113,"parentId":98},"47140","Wetenschap - andere",{"id":115,"title":116,"parentId":98},"47106","Biofysica",{"id":118,"title":119,"parentId":98},"47105","Biologie","AMSTERDAM, Nederland, 8 april 2019 - Alnylam Pharmaceuticals (NASDAQ: ALNY), een leidend RNA-interferentie (RNAi) farmaceutisch bedrijf, heeft vandaag aangekond",{"hasError":122,"data":123},true,{"description":124,"errorCode":125},"resource does not exist",404]